Publication Name	World Journal of Clinical Oncology
Manuscript ID	106798
Country	China

Category	Gastroenterology & Hepatology
Manuscript Type	Retrospective Cohort Study
Article Title	Transarterial chemoembolization plus lenvatinib with or without protein-1 inhibitor for hepatocellular carcinoma with portal vein tumor thrombus
Manuscript Source	Unsolicited Manuscript
All Author List	Shuai Liu, Yao-Hui Liu, Hong-Bo Ni, Jia-Jian Li, Ze-Tao Wu, Luo-Luo Wang, Yi Ruan and Xin-Hua Zhou
Funding Agency and Grant Number	Funding Agency Grant Number Zhejiang Province Medicine and Health Science and Technology Project No. 2023KY239 Zhejiang Province Traditional Chinese Medicine Science and Technology Plan Project No. 2024ZL949
Corresponding Author	Xin-Hua Zhou, Chief Physician, Professor, Department of Hepatobiliary and Pancreatic Surgery, Li Huili Hospital Affiliated to Ningbo University, No. 1111 Jiangnan Road, Yinzhou District, Ningbo 315000, Zhejiang Province, China. zhouxinhua1002@163.com
Key Words	Transarterial chemoembolization; Hepatocellular carcinoma; Portal vein tumor thrombus; Programmed cell death protein-1; Propensity score matching; Lenvatinib
Core Tip	This study evaluates the efficacy and safety of transarterial chemoembolization (TACE) combined with lenvatinib plus death protein-1 inhibitors (TACE-L-P) vs TACE combined with lenvatinib (TACE-L) in treating hepatocellular carcinoma with portal vein tumor thrombus (HCC-PVTT). The TACE-L-P regimen showed significantly improved overall survival, progression-free survival, and response rates compared to TACE-L. The safety profiles were comparable, with no severe treatment-related adverse events. These findings suggest that TACE-L-P may be a promising therapeutic option for HCC-PVTT patients.
Citation	Liu S, Liu YH, Ni HB, Li JJ, Wu ZT, Wang LL, Ruan Y, Zhou XH. Transarterial chemoembolization plus lenvatinib with or without protein-1 inhibitor for hepatocellular carcinoma with portal vein tumor thrombus. World J Clin Oncol 2025; In press

Received	2025-03-09 09:28
Peer-Review Started	2025-03-09 09:28
To Make the First Decision
Return for Revision	2025-03-25 08:07
Revised	2025-04-07 16:30
Second Decision	2025-04-29 02:37
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2025-04-29 07:47
Articles in Press	2025-04-29 07:47
Publication Fee Transferred	2025-04-09 12:19
Edit the Manuscript by Language Editor
Typeset the Manuscript

ISSN	2218-4333 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com